Form 4: Vanda Pharmaceuticals Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Joakim Wijkstrom, SVP and Chief Marketing Officer of Vanda Pharmaceuticals, disposed of shares to cover tax obligations related to vested RSUs.
Summary
- On March 1, 2025, Joakim Wijkstrom, SVP, Chief Marketing Officer of Vanda Pharmaceuticals, disposed of 15,520 shares of common stock.
- The shares were sold at a price of $4.76.
- The transaction was to cover tax withholding obligations related to the settlement of vested Restricted Stock Units (RSUs).
- Following the transaction, Wijkstrom directly owns 239,269 shares of Vanda Pharmaceuticals.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing represents a routine transaction to cover tax obligations, with no indication of positive or negative implications for the company's performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders. This transaction appears to be a routine sale to cover tax obligations, which is a common occurrence when RSUs vest.
Key Dates
| Date | Description |
|---|---|
| 03/01/2025 | Date of transaction: Joakim Wijkstrom disposed of shares. |
| 03/04/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.